TRLs and their remnants are increasingly acknowledged as causal contributors to ASCVD, with apoB likely serving as the main driver of this risk, particularly in patients with DM, MetS, or residual risk despite LDL-C control. The gene discussed is APOB; the disease is metabolic syndrome.